Janux Therapeutics (JANX) Stock: Prostate Cancer Drug Data Sends Shares Plunging 41%

TLDR

• Janux Therapeutics stock crashed 41% after releasing Phase 1 trial data for JANX007, its prostate cancer treatment
• The drug showed partial responses in 30% of patients with progression-free survival of 7.9 to 8.9 months
• Analysts slashed price targets by 20-36%, citing limited patient data and questions about competitive positioning
• Investors worry JANX007 may struggle against Novartis’s Pluvicto, which has shown better results with 49% response rate and 11.6 months progression-free survival
• Wall Street maintains Strong Buy rating with average price target of $75.42, suggesting 122% upside potential

Janux Therapeutics shares took a beating Tuesday after the company released what it labeled “positive” trial data for its prostate cancer treatment. Investors didn’t see it that way.

Janux Therapeutics, Inc., JANX

The biotech firm dropped 41% in premarket trading following the release of early-stage data for JANX007. The drug targets metastatic castration-resistant prostate cancer, an advanced form that has spread throughout the body.

JANX007 is a T-cell engager, a type of immunotherapy that directs the body’s immune cells to attack cancer cells. The treatment targets PSMA, a protein found in prostate cancer tumors.

The Phase 1 data showed anti-tumor activity with partial responses in 30% of evaluable patients. Radiographic progression-free survival ranged from 7.9 to 8.9 months. The company called the safety profile “manageable.”

That wasn’t enough to satisfy Wall Street. The real issue? Limited progress over the past year.

Stifel analyst Stephan Willey cut his price target to $38 from $46 while keeping a Buy rating. He noted the company has generated a “limited amount of incremental patient data” over the past 12 months. Too many questions remain unanswered about dosing strategy and when Phase 3 trials might begin.

Analysts Slash Price Targets

H.C. Wainwright analyst Swayampakula Ramakanth dropped his target to $45 from $70. He called the results “mixed” and said JANX007 will likely be a “show me” story until more data emerges. The overall efficacy profile deteriorated on key endpoints, he noted.

Clear Street analyst Kaveri Pohlman maintained her Buy rating but cut her target from $80 to $32. That’s a 60% reduction. She cited “more pragmatic” market-entry timelines.

The selloff marks a sharp reversal from nearly a year ago. Back then, shares soared double digits when Janux shared earlier Phase 1 data. All trial patients had achieved at least a 50% reduction in prostate-specific antigen levels.

Competition Concerns

The elephant in the room is Novartis’s Pluvicto, already approved and on the market. In later-stage trials, Pluvicto showed a 49% overall response rate. Its median progression-free survival hit 11.6 months. That’s better than JANX007’s current numbers.

Investors want to know how Janux plans to compete. They’re concerned about execution risk and timing for Phase 3 trials. Competition in the prostate cancer space is heating up.

Willey believes the sharp drop seems too extreme given the strength of Janux’s platform. His lower price target reflects higher execution risk specifically for JANX007. The near-term catalyst picture looks limited.

Despite the brutal selloff, Wall Street analysts maintain a Strong Buy consensus rating. Fourteen analysts recommend buying the stock, with one Hold rating. The average price target sits at $75.42, suggesting 122% upside from current levels.

That optimism may hinge on future data releases and how the company addresses investor concerns. The correlation between high-quality PSA responses and treatment durability remains a positive sign, according to Willey.

The company will need to generate more patient data and clarify its development strategy. Investors want answers about dosing, trial timelines, and competitive positioning against Pluvicto.

The post Janux Therapeutics (JANX) Stock: Prostate Cancer Drug Data Sends Shares Plunging 41% appeared first on Blockonomi.